Drug Developer City Therapeutics Files for US Initial Public Offering

Drug developer City Therapeutics filed for an initial public offering in the U.S. on Thursday, signaling its intent to raise capital from public markets and list on the Nasdaq exchange.

The Offering Details

The Cambridge, Massachusetts-based company plans to list its shares under the proposed ticker symbol CTY, according to a statement citing the filing. The company intends to sell new shares in the offering, though the number of shares and the proposed price range were not disclosed.

A consortium of investment banks is managing the deal. The listed underwriters for the offering are:

• Goldman Sachs
• Jefferies
• Stifel
• Oppenheimer

Ad

Market Context

This filing adds to the pipeline of life sciences companies seeking to go public. The performance of biotech IPOs is often closely monitored by investors as a gauge of market appetite for high-growth but also high-risk sectors, which are heavily dependent on regulatory approvals and clinical trial outcomes.

The final terms of the IPO and its reception will provide an indicator of investor confidence in the broader biotechnology industry. Further details on City Therapeutics' financials, its drug development pipeline, and the intended use of proceeds will be made available in its formal registration statement with the U.S. Securities and Exchange Commission.